Article thumbnail
Location of Repository

Cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection

By Marijn Rutgers, Daniël BF Saris, Wouter JA Dhert and Laura B Creemers
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2911907
Provided by: PubMed Central

Suggested articles

Citations

  1. (2007). A: Resveratrol inhibits IL-1 beta-induced stimulation of caspase-3 and cleavage of PARP in human articular chondrocytes in vitro.
  2. (2007). and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis.
  3. (2009). Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage
  4. (2002). Cawston TE: The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum
  5. (2006). chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
  6. (1994). Comparative and combined effects of interleukin 6, interleukin 1 beta, and tumor necrosis factor alpha on proteoglycan metabolism of human articular chondrocytes cultured in agarose.
  7. (1987). Criteria for the classification of osteoarthritis of the knee and hip.
  8. (2002). CW: Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther
  9. (1993). de Vries JE: Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol
  10. (1989). DJ: Induction of articular cartilage degradation by recombinant interleukin 1 alpha and 1 beta. Connect Tissue Res
  11. (2002). E: Effects of TNFalpha-antagonists on nitric oxide production in human cartilage. Osteoarthritis Cartilage
  12. (2007). Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum
  13. (2000). Elson CJ: Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis. Osteoarthritis Cartilage
  14. (2004). F: The regulation of chondrocyte function by proinflammatory mediators: prostaglandins and nitric oxide. Clin Orthop Relat Res
  15. (2003). Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress. Osteoarthritis Cartilage
  16. Goldring MB: The role of cytokines in cartilage matrix degeneration in osteoarthritis.
  17. (1988). Grodzinsky AJ: Fluorometric assay of DNA in cartilage explants using Hoechst 33258. Anal Biochem
  18. (2000). HP: Interleukin-1beta induces different gene expression of stromelysin, aggrecan and tumornecrosis-factor-stimulated gene 6 in human osteoarthritic chondrocytes in vitro. Pathobiology
  19. (1995). Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA. The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor. Lab Invest
  20. (1997). In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum
  21. (2005). Instability of cytokines at body temperature.
  22. (1999). JM: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature
  23. (1996). JP: Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum
  24. (1992). JP: The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum
  25. (2002). JP: The role of cytokines in osteoarthritis pathophysiology. Biorheology
  26. (2008). JS: Mechanism of proteoglycan aggregate degradation in cartilage stimulated with oncostatin M. Osteoarthritis Cartilage
  27. (1994). Leung DY: IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol Rev
  28. (1993). Metalloprotease activity, phospholipase A2 activity and cytokine concentration in osteoarthritis synovial fluids. Osteoarthritis Cartilage
  29. (2007). Muneta T: Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum
  30. (2006). Osch GJ: Age-related differences in articular cartilage wound healing: a potential role for transforming growth factor beta1 in adult cartilage repair. Adv Exp Med Biol
  31. (1999). Pelletier JP: In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression.
  32. (1989). Pettipher ER: Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol
  33. (1996). production by human articular chondrocytes. Osteoarthritis Cartilage
  34. (2008). Rannou F: A high interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee osteoarthritis.
  35. (2000). Reginster JY: Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthritis Cartilage
  36. (2007). Reinecke JA: Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy. BioDrugs
  37. (2005). Results from a double blind, placebo-controlled, multicenter trial of a single intraarticular injection of anakinra (kineret (R)) in patients with osteoarthritis of the knee. Arthritis and Rheumatism
  38. (2005). Rijkers GT: Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies.
  39. (2003). Rijkers GT: Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol
  40. (2000). SA: IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol
  41. (2008). Saris DB: Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage
  42. (2009). Seyfert-Margolis V: Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.
  43. (1990). SP: Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.
  44. (1997). Synovial membrane inflammation and cytokine production in patients with early osteoarthritis.
  45. (1973). The quantitative measurement of Alcian Blueglycosaminoglycan complexes.
  46. (1997). Thonar EJ: Effects of recombinant human osteogenic protein 1 on the production of proteoglycan, prostaglandin E2, and interleukin-1 receptor antagonist by human articular chondrocytes cultured in the presence of interleukin-1beta. Arthritis Rheum
  47. (2006). Tuan RS: Effects of TGF-beta1 and triiodothyronine on cartilage maturation: in vitro analysis using long-term high-density micromass cultures of chick embryonic limb mesenchymal cells.
  48. (1996). WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum
  49. (2003). Wehling P: The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res
  50. (1996). Zum Buschenfelde KH, Marker-Hermann E: Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.